OpportunityAnalyzer: Pancreatic Cancer Opportunity Analysis and Forecasts to 2017
Reportstack, provider of premium market research reports announces the addition of OpportunityAnalyzer: Pancreatic Cancer Opportunity Analysis and Forecasts to 2017 market report to its offering
With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the highest unmet need in oncology. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the pancreatic cancer market with coverage of both the early stage resectable and advanced settings. Celgene’s Abraxane was...
View full press release